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Background: MDM2 dimerization is required for p53 ubiquitination and degradation.
Results: MDM2-MDM2 and MDM2-MDMX interactions occur through different mechanisms.
Conclusion: MDM2-MDMX interaction requires the proper MDM2 RING domain structure, whereas MDM2-MDM2 inter-
action does not require the proper RING structure but requires the MDM2 acidic domain.
Significance: Our findings offer mechanistic details of MDM2 dimerization, which are important for understanding p53
regulation as it relates to cancer.
The oncoprotein murine double minute 2 (MDM2) is an E3
ligase that plays a prominent role in p53 suppression by promot-
ing its polyubiquitination and proteasomal degradation. In its
active form, MDM2 forms homodimers as well as heterodimers
with the homologous protein murine double minute 4 (MDMX),
both of which are thought to occur through their respective
C-terminal RING (really interesting new gene) domains. In this
study, using multiple MDM2 mutants, we show evidence sug-
gesting that MDM2 homo- and heterodimerization occur
through distinct mechanisms because MDM2 RING domain
mutations that inhibit MDM2 interaction with MDMX do not
affect MDM2 interaction with WT MDM2. Intriguingly, dele-
tion of a portion of the MDM2 central acidic domain selectively
inhibits interaction with MDM2 while leaving intact the ability
of MDM2 to interact with MDMX and to ubiquitinate p53. Fur-
ther analysis of an MDM2 C-terminal deletion mutant reveals
that the C-terminal residues of MDM2 are required for both
MDM2 and MDMX interaction. Collectively, our results suggest
a model in which MDM2-MDMX heterodimerization requires
the extreme C terminus and proper RING domain structure
of MDM2, whereas MDM2 homodimerization requires the
extreme C terminus and the central acidic domain of MDM2,
suggesting that MDM2 homo- and heterodimers utilize distinct
MDM2 domains. Our study is the first to report mutations capa-
ble of separating MDM2 homo- and heterodimerization.
True to its title of “guardian of the genome,” the tumor sup-
pressor p53 is a transcription factor that promotes the tran-
scription of an array of genes responsible for preventing cells
from proliferating in the presence of DNA damage. Various
stresses, such as DNA damage, activate p53, which, in turn,
up-regulates several genes involved in cell cycle arrest and apo-
ptosis (1– 4). As a major factor involved in the inhibition of cell
growth and division, the TP53 gene is mutated in many differ-
ent types of cancer (5). Interestingly, many cancers that do not
harbor a mutation directly affecting p53 often harbor muta-
tions in genes that regulate p53, resulting in p53 inactivation
(6 – 8). The oncoprotein murine double minute 2 (MDM2)2 is a
particularly important p53 regulator that is overexpressed in
nearly one-third of sarcomas that harbor wild-type p53, consis-
tent with the idea that the overexpression of MDM2 could sub-
stitute for p53 mutation (9).
MDM2 is best known for its role as an E3 ubiquitin ligase that
ubiquitinates p53, thereby targeting p53 for proteasomal deg-
radation (10 –12). Knockout of Mdm2 results in embryonic
lethality in mice that can be rescued through the concomitant
deletion of p53, emphasizing the importance of MDM2 in p53
regulation (13). In its active form, MDM2 forms homodimers
and/or heterodimers with its homologous partner MDMX,
presumably through their C-terminal really interesting new
gene (RING) domains (14). In addition to its role in dimeriza-
tion, the RING domain of MDM2 is also necessary for catalyz-
ing the transfer of ubiquitin to p53 (15). Although MDMX con-
tains a RING domain that is very similar to that of MDM2,
MDMX lacks appreciable E3 ligase activity toward p53. None-
theless, the MDM2-MDMX heterodimer appears to be
required for p53 degradation, at least during embryonic devel-
opment, because mice harboring MDMX deletion or MDMX
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mutations that prevent heterodimerization with MDM2 show
an embryonic lethal phenotype that can be rescued by concom-
itant p53 deletion (16, 17).
Many of the studies that have contributed to our understand-
ing of MDM2 dimerization have used isolated domains of
MDM2, such as the RING domain (human MDM2 residues
384 – 491 (18, 19)). Although the study of isolated protein
domains can offer insights into the function of individual pro-
tein domains, these studies fail to account for the behavior of
these domains in the context of the full-length protein. There-
fore, a comprehensive understanding of MDM2 behavior and
function can only be obtained by studying the full-length pro-
tein. In this study, we use several known and novel MDM2
mutant constructs in the context of the full-length protein to
show that MDM2-MDM2 interaction requires the central
acidic domain and the extreme C-terminal residues of MDM2,
whereas MDM2-MDMX interaction requires the proper RING
domain structure and the extreme C-terminal residues of
MDM2.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents—U2OS and H1299 cells were
obtained from the ATCC and were maintained in DMEM sup-
plemented with 10% fetal bovine serum (Sigma or Gibco), 100
units/ml penicillin, and 100 g/ml streptomycin (Gibco). Cells
were grown at 37 °C in a humidified incubator in the presence
of 5% CO2. MG132 was purchased from Calbiochem (catalog
no. 474790). Cycloheximide was purchased from Sigma (cata-
log no. C7698). Phusion polymerase (catalog no. M0530S) and
all restriction enzymes were purchased from New England Bio-
labs. XtremeGene HP transfection reagent was purchased from
Roche through the University of North Carolina Tissue Culture
Facility, and transient transfections were performed according
to the instructions of the manufacturer. Mouse anti-actin
(MAB1501, Chemicon), mouse anti-p53 (catalog no. DO-1,
Labvision, AB-6, catalog no. MS-187P), mouse anti-FLAG (M2,
Sigma, catalog no. F3165), and mouse anti-HA (16B12,
Covance, catalog no. MMS101P) antibodies were purchased.
Mouse anti-MDM2 (4B11 and 2A10) and rabbit anti-myc (9E10)
antibody supernatants were obtained from hybridoma cell lines.
Cloning and Plasmids—MDM2 mutants were generated by
using the QuikChange II XL site-directed mutagenesis protocol
(Agilent Technologies, catalog no. 200521). Briefly, wild-type
human MDM2 encoded in the pCMV mammalian expression
vector was used as a template for all site-directed mutagenesis
reactions. PCR reactions (50 l total volume) contained 100 g
of template plasmid DNA, 20 pmol of forward primer, 20 pmol
of reverse primer, 1 Phusion polymerase buffer, 50 M dNTPs
(Thermo Scientific, catalog no. R0182), 2 units of Phusion po-
lymerase, and distilled water. The primers used were as follows:
N447A (Tm 55 °C), gtgatttgtcaaggtcgacctaaagccggctgcattgtcca-
tggcaaaac (forward) and gtttgccatggacaatgcagccggctttaggtcga-
ccttgacaaatcac (reverse); N447D (Tm 55 °C), gtgatttgtcaaggtcg-
acctaaagacggctgcattgtccatggcaaaac (forward) and gttttgccatgg-
acaatgcagccgtctttaggtcgaccttgacaaatcac (reverse); C-terminal
deletion (Tm 55 °C), ccctgcccagtatgtagatagttgacctgtctataagag-
aatt (forward) and aattctcttatagacaggtcaactatctacatactgggcaggg
(reverse); RING deletion (Tm 55 °C), cccttaatgccattgaacaaccaa-
ttcaaatgattg (forward) and caatcatttgaattggttgttcaatggcattaaggg
(reverse); RING and C-terminal deletion (Tm 55 °C), cccttaatg-
ccattgaatagttgacctgtctataagagaatt (forward) and aattctcttataga-
caggtcaactattcaatggcattaaggg (reverse); and acidic domain
deletion (Tm 60 °C), atcaggattcagtttcagatcaggaaatttccttagctgac-
tattgg (forward) and ccaatagtcagctaaggaaatttcctgatctgaaactga-
atcctgat (reverse). Mutagenesis primers were designed to
harbor a novel restriction endonuclease site that did not alter
the protein coding sequence and were used to amplify the in-
tended product using a thermocycler (Applied Biosystems,
model 2720) with the following program: 98 °C for 4 min, then
30 cycles of 98 °C for 30 s, 60 °C for 30 s, and 72 °C for 5 min. A
final extension step at 72 °C for 10 min was performed after the
final cycle. Reactions were digested with DpnI (New England Biol-
abs) for 2 h, and then 10 l of each reaction was transformed into
chemically competent XL-1 blue Escherichia coli cells. All clones
were submitted to the University of North Carolina Genome An-
alysis Facility for sequence verification.
Transfections—Cells were plated in 6-well plates overnight,
and transfections were performed using XtremeGene HP
transfection reagent (Roche) according to the instructions of
the manufacturer. Briefly, cells were transfected at 90% con-
fluence with a mixture of 2 g of total DNA and 6 l of trans-
fection reagent. All transfections included a GFP plasmid to
visually confirm transfection efficiency (in all transfections, at
least 50% of cells were GFP-positive). Twenty-four hours after
the transfection, the indicated treatment was applied, or the
cells were collected and lysed for Western blotting.
Immunoprecipitation—Cells were transfected with the ap-
propriate plasmids for 24 h, after which the cells were lysed in
0.1% Nonidet P-40 buffer containing 1 protease inhibitor
mixture (leupeptin, catalog no. L2884; aprotinin, catalog no.
A1155; benzamidine, catalog no. B6506; and trypsin inhibitor,
catalog no. T9003; all from Sigma), 1 mM PMSF (Sigma, catalog
no. P7626), 1 mM NaVO3 (Fisher Scientific, catalog no. S454-
50), and 1 mM DTT (Roche, catalog no. 03117014001) for 2 h.
Lysates (500 g of each) were probed with 5 l of EZ-view
anti-FLAG M2 affinity gel (Sigma, catalog no. F2426) by rotat-
ing the samples at 4 °C for 2 h to overnight. Beads were washed
three times in 0.1% Nonidet P-40 lysis buffer, after which the
beads and inputs were analyzed by Western blotting.
Half-life Assay—U2OS cells were transfected with the indi-
cated vectors for 24 h, after which cycloheximide (100 g/ml)
was added to all samples. Cells were collected in 0.5% Nonidet
P-40 lysis buffer containing 1 protease inhibitor mixture, 1
mM PMSF, 1 mM NaVO3, and 1 mM DTT at the indicated time
point after cycloheximide addition. Cells were lysed for 2 h by
rotation at 4 °C, after which the samples were centrifuged, and
the supernatants were collected. Lysates were separated by
SDS-PAGE and subjected to Western blotting for the indicated
proteins. Bands were quantified after normalization to actin
and plotted as the amount of protein remaining relative to time
0. Bands were compared quantitatively by using ImageJ soft-
ware version 1.48.
Western Blotting—Cell lysates (100 g/sample) were sepa-
rated on 10% or 12.5% SDS-PAGE gels, after which the proteins
were transferred to nitrocellulose membranes (Bio-Rad).
Transfers were assessed by staining the membranes with Pon-
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ceau S (Sigma, catalog no. P3504) for 5 min, followed by several
brief washes with double-distilled H2O. Membranes were
blocked for at least 1 h in phosphate-buffered saline containing
5% nonfat milk and 0.1% Tween 20. Membranes were then
incubated with the appropriate primary antibody diluted in
blocking buffer for 2 h to overnight. Membranes were washed
three times in phosphate-buffered saline containing 0.1%
Tween 20 and then incubated with the appropriate HRP-con-
jugated secondary antibody diluted in blocking buffer for 1 h.
Membranes were washed four times in PBS-T and then devel-
oped with Supersignal West Pico chemiluminescent substrate
according to the instructions of the manufacturer (Pierce, cat-
alog no. 34080).
In Vivo Ubiquitination Assay—Equal amounts of U2OS or
H1299 cells were transfected with the indicated plasmid con-
structs for 24 h, and then the cells were trypsinized and col-
lected. One-fifth of each sample was lysed with 0.1% Nonidet
P-40 lysis buffer as input. The remaining cells were boiled in
SDS lysis buffer containing 1 protease inhibitor, 1 mM PMSF,
1 mM NaVO4, and 1 mM DTT for 10 min. Then the lysates were
diluted into 0.1% Nonidet P-40 lysis buffer containing protease
inhibitors and subjected to immunoprecipitation using anti-
FLAG beads. Western blotting was performed to probe for the
indicated proteins.
RESULTS
MDM2 Residue Asn-447 Is Important for p53 Degradation—
Kostic et al. (20) performed a detailed investigation of MDM2-
MDMX RING domain binding by NMR (20). In this study,
radiolabeled purified MDM2 RING domains were titrated with
unlabeled purified MDMX RING domains, and differences in
the heteronuclear single quantum coherence spectra were
obtained for each MDM2 residue within the RING domain
upon MDMX binding. The greatest chemical shift occurred at
asparagine residue 447 in MDM2, suggesting that Asn-447 may
be important for MDM2-MDMX binding. Initial analysis of the
MDM2 sequence indicated that many of the residues within the
C-terminal MDM2 RING domain show a high degree of iden-
tity among different species. Asn-447 is conserved in many spe-
cies from humans to zebrafish, consistent with the idea that this
residue serves an important role in MDM2 function (Fig. 1E).
Additionally, upon analyzing the MDM2-MDMX RING do-
main heterodimer crystal structure (21), Asn-447 appears to
form an intramolecular hydrogen bond with the backbone
FIGURE 1. A, PyMOL image on the basis of the published crystal structure of the human MDM2 (green)-MDMX (blue) RING domain heterodimer. Residues
Phe-462 and Asn-447 are shown as stick figures. B, close-up image of A depicting the intramolecular bond between the Asn-447 side chain and the amino group
of Phe-462. C, PyMOL image simulating the conservative N447D mutation. D, PyMOL image simulating the non-conservative N447A mutation. E, protein
sequence alignment for the MDM2 RING domain (human residues 437– 479) in several species. F, diagram of MDM2 with amino acid positions of the AD
(245–295), RING (437– 479), and extreme C terminus (479 – 491) indicated. G, U2OS cells (WT p53) transfected with empty vector or untagged or FLAG-tagged
MDM2 constructs and then blotted for MDM2 (4B11) and p53 (DO-1). H, H1299 cells (p53-null) cotransfected with WT p53 and empty vector or untagged or
FLAG-tagged MDM2 constructs and then blotted for MDM2 (4B11) and p53 (DO-1). I, U2OS cells were transfected with empty vector or FLAG-MDM2 constructs
for 24 h and then treated for 2.5 h with 10 M MG132 and 100 g/ml cycloheximide. Membranes were blotted for MDM2 (2A10) and p53 (DO-1).
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amino group of Phe residue 462 (Fig. 1, A and B). To determine
whether the Asn-447 side chain is indeed important for MDM2
function, we used site-directed mutagenesis to convert the
Asn-447 residue to aspartic acid or alanine (Fig. 1F). We pre-
dicted that aspartic acid, which contains a side chain of compa-
rable size and polarity to asparagine, should maintain the
hydrogen bond and the proper three-dimensional structure
and function of MDM2 (Fig. 1C). However, the alanine substi-
tution mutant, which lacks a side chain oxygen residue and is
considerably smaller than the asparagine side chain, should lose
the ability to bond with Phe-462, thereby preventing the proper
structure and function of MDM2 (Fig. 1D).
To test the importance of Asn-447 in MDM2 function,
MDM2 point mutation constructs were assembled in untagged
and FLAG-tagged expression plasmids. Consistent with our
modeling predictions, endogenous p53 levels decreased in cells
transfected with either WT MDM2 or the N447D mutant com-
pared with the empty vector control. Likewise, p53 levels
increased in cells transfected with the E3-dead C464A mutant
or the N447A mutant (Fig. 1G). These results suggest that
although the N447A mutation inhibits the ability of MDM2 to
degrade p53, the N447D mutation does not appreciably affect
MDM2-mediated p53 degradation. We observed similar
results when we tested these mutants on exogenously overex-
pressed p53 in H1299 cells (p53-null, Fig. 1H). Although cells
transfected with the N447D mutant showed significant p53
degradation, a noticeable increase in p53 levels was observed
with the N447D mutant compared with WT MDM2, which
reflects decreased E3 ligase activity, likely because of differ-
ences between the Asp side chain and the naturally occurring
Asn side chain. Treatment of the transfected cells with MG132
prevented degradation of p53 and MDM2 by WT MDM2 and
the N447D mutant, suggesting that degradation occurs pre-
dominantly through the proteasome (Fig. 1I).
The N447A Half-life Increases because of Lack of Ubiquitina-
tion Activity—To further determine the effect of the Asn-447
mutations on p53 and MDM2 stability, half-life assays were
conducted for the N447A and N447D mutants in U2OS cells.
Expression of the E3-active WT or N447D mutant constructs
shortened the half-life of p53 (58 and 69 min, respectively, com-
pared with 116 min for the empty vector), which is consistent
with intact MDM2 E3 activity (Fig. 2A). Conversely, the p53
half-life was extended dramatically in the presence of the
C464A or N447A MDM2 mutants (over 210 min for both com-
pared with 116 min for the empty vector), consistent with
diminished MDM2 E3 activity (Fig. 2A). Analysis of the half-life
of the overexpressed MDM2 revealed a similar trend where
WT and N447D mutants showed relatively short half-lives (69
and 77 min, respectively) compared with the C464A and
N447A mutants (210 min for both), consistent with the abil-
ity of ectopically overexpressed WT and N447D MDM2 pro-
teins to promote their own degradation (Fig. 2A).
Next we conducted in vivo ubiquitination assays to deter-
mine whether the MDM2 mutants show differences in p53
and/or MDM2 ubiquitination. To assess p53 ubiquitination,
H1299 cells (p53-negative) were transfected with FLAG-p53,
HA-ubiquitin, and untagged MDM2 constructs for 24 h. As in
previous results (Fig. 2A), WT MDM2 and the N447D mutant
polyubiquitinated p53, whereas the C464A and N447A
mutants were unable to ubiquitinate p53 (Fig. 2B). To assess
MDM2 autoubiquitination, the FLAG-MDM2 constructs were
individually transfected into H1299 cells along with HA-ubiq-
uitin. Consistent with the p53 ubiquitination assay results, the
WT and the N447D mutant showed autoubiquitination ladder-
ing, whereas the C464A and N447A mutants displayed signifi-
cantly less laddering (Fig. 2C).
RING-disruptive Mutations Inhibit MDM2 Binding to
MDMX but Not to MDM2—Because MDM2 is thought to
require homo- and/or heterodimerization with MDMX
to function as an effective E3 ligase (11, 14), we sought to deter-
mine how these mutations affect MDM2 homo- and het-
erodimerization. To this end, U2OS cells were cotransfected
with myc-tagged WT MDMX and each of the FLAG-MDM2
mutant constructs and were then subjected to coimmunopre-
cipitation (co-IP). As expected, the MDM2 constructs capable
of degrading p53 (WT and N447D) formed robust het-
erodimers, whereas MDM2 constructs incapable of degrading
p53 (C464A and N447A) failed to heterodimerize (Fig. 3A). We
noticed a consistent decrease in heterodimerization between
MDMX and the N447D mutant relative to WT MDM2, sug-
gesting that the N447D mutation marginally affects MDM2-
MDMX binding.
To determine whether the MDM2 mutant constructs could
interact with MDM2, we conducted a similar co-IP experiment
with WT myc-MDM2 instead of myc-MDMX. Surprisingly, all
constructs were able to pull down WT MDM2 to similar
extents (Fig. 3B). Because the RING domain of MDM2 has been
thought to be responsible for MDM2 homodimerization, we
expected that the C464A and N447A mutants, which were
unable to heterodimerize with MDMX, would also fail to inter-
act with MDM2. However, despite harboring point mutations
that prevent binding with MDMX, C464A and N447A mutant
MDM2 maintained robust binding with WT MDM2 to an
extent similar to WT MDM2 itself, suggesting that MDM2-
MDMX and MDM2-MDM2 interactions require different sets
of residues for binding.
Deletion of the Extreme C-terminal Residues Prevents MDM2
Interaction with MDM2 and MDMX—Previous studies have
shown that the MDM2 sequence at the extreme C terminus is
necessary for homo- and heterodimer formation (18, 22).
Because our co-IP results suggested that MDM2 homo- and
heterodimers may require different residues, we sought to
determine the effect of an extreme C terminus deletion of
MDM2 on its ability to interact with full-length MDM2. To this
end, we constructed MDM2 C-terminal deletion mutants lack-
ing the RING domain (amino acids 437– 479, RING), the
extreme C-terminal 12 residues (480 – 491, C-term), or both
the RING domain and the C-terminal residues (437– 491,
RING/C-term) (Fig. 4A). Consistent with our expectations,
all of these constructs lacked the ability to degrade endoge-
nous p53 (Fig. 4B). Furthermore, co-IP experiments con-
ducted to determine their ability to bind MDMX or MDM2
revealed that all three deletion constructs failed to interact
with either MDMX or MDM2 full-length constructs (Fig. 4,
C and D). These data suggest that although the proper struc-
ture of the RING domain may not be required for MDM2-
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MDM2 interaction, the presence of the RING domain and
the C-terminal residues that lie downstream of the RING
domain of MDM2 are necessary for interaction with both
MDMX and MDM2.
The MDM2 Acidic Domain Is Necessary for Interaction with
MDM2 but Not with MDMX—MDM2 has been reported to
dimerize through RING-acidic domain (AD) interactions (23).
However, a more recent study has suggested that AD-RING
interactions occur intramolecularly, which may actually be
more physiologically relevant than potential intermolecular
AD-RING domain interactions. Consistent with the idea that
intermolecular RING-AD interactions may not significantly
affect MDM2-MDM2 binding in the cellular milieu, the
RING MDM2 mutant, which harbors an intact AD, is
severely impaired in its ability to bind to WT MDM2, which
contains both the AD and the RING domain (Fig. 4D). None-
theless, to investigate the possible effects of the AD on the
observed interactions of our mutant constructs, we deleted a
portion of the AD (245–295) in the WT, C464A, N447A,
and N447D constructs to determine the effect of AD deletion
on MDM2 dimerization and p53 degradation (Fig. 5A). Con-
sistent with previous reports, AD deletion inhibited the degra-
FIGURE 2. A, U2OS cells were transfected with constructs encoding MDM2 for 24 h and then chased with 100 g/ml cycloheximide (CHX) for various amounts
of time. Lysates were resolved by SDS-PAGE and then probed by Western blot analysis for p53 (DO-1) and MDM2 (4B11). B and C, H1299 cells were cotransfected
with FLAG-p53, HA-ubiquitin, and one of the untagged MDM2 constructs (B) or with HA-ubiquitin and FLAG-MDM2 (C) for 24 h. Cells were subjected to a
ubiquitination assay, probing with anti-HA antibody to detect ubiquitinated p53 or MDM2. Inputs representing 20% of the immunoprecipitated protein are
included. IB, immunoblot.
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dation of endogenous p53 (Fig. 5B) and ectopically expressed
p53 (Fig. 5C).
Co-IP analysis for dimerization with MDMX revealed that
AD deletion does not affect heterodimer formation of WT or
N447D MDM2, consistent with the idea that heterodimeriza-
tion is necessary for ubiquitination activity (Figs. 3A and 6A).
Furthermore, these results suggest that the AD is dispensable
for heterodimerization, which likely occurs exclusively through
RING domain/C-terminal interactions. However, when ana-
lyzed for their ability to interact with WT myc-MDM2, the AD
deletion mutants displayed an inverse trend. When the AD was
deleted in the E3-dead C464A or N447A constructs, the ability
to interact with WT MDM2 was largely unaffected. How-
ever, when the AD was deleted in the E3-active WT or
N447D constructs, their ability to bind WT MDM2 was
abrogated, suggesting that MDM2-MDM2 binding depends
on the AD (Fig. 6B).
To further investigate the E3-dead (C464A and N447A) AD
deletion mutants, the extreme C-terminal residues were
deleted to determine whether these dimers require the C ter-
minus. When the extreme C terminus was deleted, the C464A
and N447A AD deletion mutants failed to interact with WT
MDM2 (Fig. 6C), suggesting that the C-terminal tail is abso-
lutely required for MDM2 dimerization.
When subjected to p53 and MDM2 in vivo ubiquitination
assays, AD deletion did not affect ubiquitination of p53 or
MDM2 (Fig. 6, D and E). These results are consistent with some
early reports analyzing various AD deletions and may suggest
that the AD is necessary for p53 and MDM2 degradation down-
stream of ubiquitination (24, 25).
To address whether coexpression of an AD-binding protein
might affect MDM2 dimer formation, we cotransfected U2OS
cells with constructs encoding FLAG-MDM2, myc-p14ARF (0,
0.1, or 0.5 g), and either myc-MDMX or myc-MDM2. After
protein extraction, the lysates were probed with anti-FLAG
beads and then examined by Western blot analysis to determine
how much myc-MDMX or myc-MDM2 was pulled down. Our
results show that p14ARF coexpression decreased MDMX lev-
els, resulting in less MDMX co-IP while increasing MDM2 lev-
els and, correspondingly, increasing the amount of MDM2
pulled down by co-IP (Fig. 6, F and G, respectively). Although it
is difficult to determine whether there is a change in binding
affinity between FLAG-MDM2 and myc-MDMX or myc-
MDM2, it appears that p14ARF at least increases the overall
amount of MDM2 homodimers and decreases the overall
amount of MDM2-MDMX heterodimers, which is consistent
with previous findings (26 –29).
DISCUSSION
MDM2 has long been known to form homodimers and het-
erodimers with the structurally related MDMX protein.
Although data have convincingly shown the importance and
necessity of MDM2-MDMX binding for p53 regulation, the
physiological significance of MDM2 homodimers remains
unknown. In vitro studies have shown that purified MDM2 in
the absence of MDMX is sufficient to ubiquitinate and, pre-
sumably, elicit the degradation of p53 (11, 22). Furthermore,
several independent mouse studies have shown that, when
MDM2 is present but unable to bind MDMX, embryonic devel-
opment progresses to a later stage than Mdm2 knockout mice
(embryonic day 7.5 or greater versus embryonic day 5.5), sug-
gesting that MDM2 alone may offer a primitive mechanism of
p53 control (13, 16, 17, 30 –32). MDM2 homodimers are indeed
stable enough to be detected when overexpressed in vitro and in
cell-based assays, suggesting that MDM2 homodimers could
also exist in vivo (20, 26).
To better understand MDM2 homodimers and MDM2-
MDMX heterodimers, detailed crystal structures of the two
dimers could be particularly valuable. However, complete crys-
tal structures of MDM2 dimers remain elusive. Therefore,
many structure- and mechanism-based MDM2 studies have
focused on isolated MDM2 domains such as the RING domain.
Although these studies have provided valuable insights into the
FIGURE 3. A and B, U2OS cells were cotransfected with constructs encoding
myc-MDMX (A) or myc-MDM2 (B) and each of the FLAG-MDM2 constructs
for 24 h. Cell lysates were subjected to immunoprecipitation, resolved by
SDS-PAGE, probed with anti-myc antibody, and reprobed with anti-FLAG
antibody. Inputs representing 10% of the immunoprecipitated protein are
included.
FIGURE 4. A, WT and mutant MDM2 constructs. B, U2OS cells were trans-
fected with empty vector or FLAG-MDM2 constructs for 24 h, and then the
cell lysates were resolved by SDS-PAGE and subjected to Western blot
probing for FLAG and p53. C and D, U2OS cells were cotransfected with
constructs encoding myc-MDMX (C) or myc-MDM2 (D) and each of the
indicated FLAG-MDM2 constructs for 24 h. Cell lysates were immunopre-
cipitated with anti-FLAG beads, resolved by SDS-PAGE, and then sub-
jected to Western blot probing with anti-myc antibody and reprobing
with anti-FLAG antibody. Inputs representing 10% of the immunoprecipi-
tated protein are included.
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binding mechanisms of the individual domains of MDM2, they
are unable to assess MDM2 binding in the context of the com-
plete protein. Although protein binding studies such as ours
require verification using purified proteins in an in vitro bind-
ing assay, our experience using purified recombinant full-
length MDM2 and MDMX protein suggests that they behave
differently under in vitro conditions compared with their
behavior in the cytoplasmic milieu (data not shown). This could
indicate that other factors, such as small proteins that bind
MDM2 or the intracellular environment itself, are required for
proper function. However, using full-length proteins overex-
pressed in cells, our study provides mechanistic insight with
respect to the domains of MDM2 that are necessary for homo-
and heterodimerization within the cell.
Using point mutations in the highly conserved Cys-464 and
Asn-447 residues, which reside within the RING domain but
interact with different residues, we show that the proper
MDM2 RING domain structure may not be necessary for inter-
action with WT MDM2 but is critical for heterodimerization
with MDMX. Previous studies investigating the conserved
zinc-coordinating residues within the RING domain have
shown the importance of these residues for heterodimerization
and p53 degradation (31, 33). Our study expounds these obser-
vations by showing that RING domain mutants (C464A and
N447A) retain the capacity to form stable homodimers with
WT MDM2 comparable with WT MDM2 itself (Fig. 3B). This
observation was unexpected because previous studies using
isolated MDM2 and MDMX RING domains have suggested
that although some residues may differ, MDM2 homodimers
and heterodimers form in a similar fashion (20, 21).
The extreme C-terminal residues have been implicated in
MDM2 RING domain homo-oligomer formation (18, 22). By
deleting a small portion of the C terminus of full-length
MDM2, our data confirm that the C-terminal residues are
required for MDM2 binding to WT MDM2 and MDMX.
Furthermore, deletion of the C-terminal 12 residues (C-
term) abrogated MDM2 interaction in all constructs tested
(WTAD, C464AAD, and N447AAD, Figs. 4D and 6C).
Although the presence of the C terminus appears to be neces-
sary for MDM2 homo- and heterodimerization, the mecha-
nisms that dictate the formation of homo- and/or heterodimers
appear to involve the MDM2 AD.
Previous studies have suggested that the AD plays a role in
MDM2 regulation and function (24, 25, 34, 35). The AD could
also play a role in regulating MDM2 protein binding, such as
dimerization preference. Deletion of the MDM2 AD can affect
binding between MDM2 and other proteins, such as p300 and
various proteasome components (36, 37). It is possible that our
AD deletion mutants lack a motif required for their interaction
with MDM2 because AD deletion from WT MDM2 selectively
inhibits binding with WT MDM2. Furthermore, we observed
an increase in MDM2-MDMX heterodimerization upon AD
deletion, suggesting that the AD may also be inhibitory toward
MDM2-MDMX heterodimerization (Fig. 6A compare lanes 1
and 3). These data collectively suggest that the AD may control
the balance between MDM2 homo- and heterodimerization.
Chen and co-workers (26 –28) and others (29) have shown that
manipulation of the MDM2 AD in response to various p53-
activating stimuli can affect MDM2 dimerization, thereby sta-
bilizing p53. We suspect that modification of the MDM2 AD or
binding by p14ARF and/or ribosomal proteins in response to
stress could also affect MDM2 homo- and heterodimerization.
Consistent with this idea, our data show that overexpression of
the MDM2-binding protein p14ARF decreases the overall
amount of MDM2-MDMX heterodimers while increasing the
amount of MDM2-MDM2 homodimers in the cell, likely by
affecting MDM2 and MDMX protein stability (Fig. 6, F and G).
Interestingly, when the AD is deleted from E3-inactive
MDM2 constructs (C464A and N447A), the ability of these
mutants to interact with WT MDM2 persists (Fig. 6B).
Although we find this observation intriguing, we are currently
unable to fully explain this E3-associated correlation. One pos-
sible explanation that will require further investigation is that
the AD functions as a trigger that, when activated, allows
homodimerization to occur through the C-terminal residues.
The unstructured state of the C464A and N447A RING
FIGURE 5. A, WT and mutant MDM2 constructs. B, U2OS cells were transfected with empty vector or FLAG-MDM2 constructs for 24 h, and then cell lysates were
subjected to Western blot probing for FLAG and p53. C, H1299 cells were cotransfected with WT p53 and empty vector or FLAG-MDM2 constructs for 24 h, and
then cell lysates were subjected to Western blotting for FLAG and p53.
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domains could constitutively expose the C terminus for
homodimerization, whereas the WT and N447D RING do-
mains maintain the C terminus in a state that allows homo- and
heterodimer formation depending on the state of the AD.
When the AD is removed from WT MDM2, then only het-
erodimers can form. Future studies investigating possible
RING structure-dependent binding mechanisms could shed
light on the binding mechanics of MDM2 and other dimeric E3
ligases.
Altogether, our results are the first to definitively show evi-
dence for differences in the mechanism of dimerization for
MDM2 homodimers and heterodimers. Our data show that
although MDM2-MDMX heterodimers form through RING
domain and extreme C-terminal contacts, MDM2 homo-
dimers form in an AD- and extreme C-terminal residue-
dependent manner (Fig. 7). To our knowledge, this AD dele-
tion mutant represents the first reported MDM2 mutation
that can selectively inhibit MDM2-MDM2 interaction while
leaving heterodimerization and E3 activity intact. We believe
that further investigation into the MDM2 AD will prove crit-
ical for a more comprehensive understanding of MDM2
regulation.
FIGURE 6. A and B, U2OS cells were cotransfected with constructs encoding myc-MDMX (A) or myc-MDM2 (B) and each of the indicated FLAG-MDM2
constructs for 24 h. A, cells were treated for 3 h with 20 M MG132 prior to lysis. Cell lysates were precipitated with anti-FLAG beads overnight and then
subjected to Western blot probing with anti-myc antibody and reprobing with anti-FLAG antibody. Inputs representing 10% of the immunoprecipitated
protein are included. C, U2OS cells were cotransfected with myc-MDM2 and each of the indicated FLAG-MDM2 constructs for 24 h. Cell lysates were
immunoprecipitated with anti-FLAG beads and then subjected to Western blot probing with anti-myc antibody and reprobing with anti-FLAG antibody.
Inputs representing 10% of the immunoprecipitated protein are included. D and E, U2OS cells were transfected with HA-ubiquitin, FLAG-p53, and one
of the untagged constructs as indicated (D) or with HA-ubiquitin and one of the FLAG-tagged constructs as indicated (E) for 24 h. Cell lysates were
immunoprecipitated with anti-FLAG beads and then subjected to Western blot probing with anti-HA antibody. Inputs representing 20% of the total
protein immunoprecipitated are included. IB, immunoblot. F and G, U2OS cells were cotransfected with constructs encoding myc-MDMX (F) or myc-
MDM2 (G) and each of the indicated FLAG-MDM2 and p14ARF constructs for 24 h. Cell lysates were precipitated with anti-FLAG beads overnight and
then subjected to Western blot probing with anti-myc antibody and reprobing with anti-FLAG antibody. Inputs representing 10% of the immunopre-
cipitated protein are included.
MDM2 Homo- and Heterodimers Require Distinct Domains
12948 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290 • NUMBER 20 • MAY 15, 2015
REFERENCES
1. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R.,
Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B.
(1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75,
817– 825
2. Nakano, K., and Vousden, K. H. (2001) PUMA, a novel proapoptotic gene,
is induced by p53. Mol. Cell 7, 683– 694
3. Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T.,
Tokino, T., Taniguchi, T., and Tanaka, N. (2000) Noxa, a BH3-only mem-
ber of the Bcl-2 family and candidate mediator of p53-induced apoptosis.
Science 288, 1053–1058
4. Di Leonardo, A., Linke, S. P., Clarkin, K., and Wahl, G. M. (1994) DNA
damage triggers a prolonged p53-dependent G1 arrest and long-term
induction of Cip1 in normal human fibroblasts. Genes Dev. 8,
2540 –2551
5. Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P.,
and Olivier, M. (2007) Impact of mutant p53 functional properties on
TP53 mutation patterns and tumor phenotype: lessons from recent devel-
opments in the IARC TP53 database. Hum. Mutat. 28, 622– 629
6. Ito, M., Barys, L., O’Reilly, T., Young, S., Gorbatcheva, B., Monahan, J.,
Zumstein-Mecker, S., Choong, P. F., Dickinson, I., Crowe, P., Hemmings,
C., Desai, J., Thomas, D. M., and Lisztwan, J. (2011) Comprehensive map-
ping of p53 pathway alterations reveals an apparent role for both SNP309
and MDM2 amplification in sarcomagenesis. Clin. Cancer Res. 17,
416 – 426
7. The Cancer Genome Atlas Research Network (2008) Comprehensive
genomic characterization defines human glioblastoma genes and core
pathways. Nature 455, 1061–1068
8. Lam, S., Lodder, K., Teunisse, A. F., Rabelink, M. J., Schutte, M., and
Jochemsen, A. G. (2010) Role of Mdm4 in drug sensitivity of breast cancer
cells. Oncogene 29, 2415–2426
9. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B.
(1992) Amplification of a gene encoding a p53-associated protein in hu-
man sarcomas. Nature 358, 80 – 83
10. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997) Mdm2 promotes the
rapid degradation of p53. Nature 387, 296 –299
11. Honda, R., Tanaka, H., and Yasuda, H. (1997) Oncoprotein MDM2 is a
ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25–27
12. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. (1997) Regulation of p53
stability by Mdm2. Nature 387, 299 –303
13. Jones, S. N., Roe, A. E., Donehower, L. A., and Bradley, A. (1995) Rescue of
embryonic lethality in Mdm2-deficient mice by absence of p53. Nature
378, 206 –208
14. Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., and
Ohtsubo, M. (1999) MDM2 interacts with MDMX through their RING
finger domains. FEBS Lett. 447, 5–9
15. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., and Weissman, A. M.
(2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for
itself and p53. J. Biol. Chem. 275, 8945– 8951
16. Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z. G., Zuo, Y., Kawai, H.,
Shadfan, M., Ganapathy, S., and Yuan, Z. M. (2011) The p53 inhibitors
MDM2/MDMX complex is required for control of p53 activity in vivo.
Proc. Natl. Acad. Sci. U.S.A. 108, 12001–12006
17. Pant, V., Xiong, S., Iwakuma, T., Quintás-Cardama, A., and Lozano, G.
(2011) Heterodimerization of Mdm2 and Mdm4 is critical for regulating
p53 activity during embryogenesis but dispensable for p53 and Mdm2
stability. Proc. Natl. Acad. Sci. U.S.A. 108, 11995–12000
18. Uldrijan, S., Pannekoek, W. J., and Vousden, K. H. (2007) An essential
function of the extreme C-terminus of MDM2 can be provided by
MDMX. EMBO J. 26, 102–112
19. Dolezelova, P., Cetkovska, K., Vousden, K. H., and Uldrijan, S. (2012)
Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily
conserved role of its length in Mdm2 activity toward p53 and indicates
structural differences between Mdm2 homodimers and Mdm2/MdmX
heterodimers. Cell Cycle 11, 953–962
20. Kostic, M., Matt, T., Martinez-Yamout, M. A., Dyson, H. J., and Wright,
P. E. (2006) Solution structure of the Hdm2 C2H2C4 RING, a domain
critical for ubiquitination of p53. J. Mol. Biol. 363, 433– 450
21. Linke, K., Mace, P. D., Smith, C. A., Vaux, D. L., Silke, J., and Day, C. L.
(2008) Structure of the MDM2/MDMX RING domain heterodimer re-
veals dimerization is required for their ubiquitylation in trans. Cell Death
Differ. 15, 841– 848
22. Poyurovsky, M. V., Priest, C., Kentsis, A., Borden, K. L., Pan, Z. Q., Pavle-
tich, N., and Prives, C. (2007) The Mdm2 RING domain C-terminus is
required for supramolecular assembly and ubiquitin ligase activity. EMBO
J. 26, 90 –101
23. Dang, J., Kuo, M. L., Eischen, C. M., Stepanova, L., Sherr, C. J., and Roussel,
M. F. (2002) The RING domain of Mdm2 can inhibit cell proliferation.
Cancer Res. 62, 1222–1230
24. Argentini, M., Barboule, N., and Wasylyk, B. (2001) The contribution of
the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene 20,
1267–1275
25. Zhu, Q., Yao, J., Wani, G., Wani, M. A., and Wani, A. A. (2001) Mdm2
mutant defective in binding p300 promotes ubiquitination but not degra-
dation of p53: evidence for the role of p300 in integrating ubiquitination
and proteolysis. J. Biol. Chem. 276, 29695–29701
26. Cheng, Q., Cross, B., Li, B., Chen, L., Li, Z., and Chen, J. (2011) Regulation
of MDM2 E3 ligase activity by phosphorylation after DNA damage. Mol.
Cell. Biol. 31, 4951– 4963
27. Cheng, Q., Chen, L., Li, Z., Lane, W. S., and Chen, J. (2009) ATM activates
p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J.
28, 3857–3867
28. Li, X., Gilkes, D., Li, B., Cheng, Q., Pernazza, D., Lawrence, H., Lawrence,
N., and Chen, J. (2012) Abnormal MDMX degradation in tumor cells due
to ARF deficiency. Oncogene 31, 3721–3732
29. Inuzuka, H., Tseng, A., Gao, D., Zhai, B., Zhang, Q., Shaik, S., Wan, L., Ang,
X. L., Mock, C., Yin, H., Stommel, J. M., Gygi, S., Lahav, G., Asara, J., Xiao,
Z. X., Kaelin, W. G., Jr., Harper, J. W., and Wei, W. (2010) Phosphorylation
by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the
SCF(-TRCP) ubiquitin ligase. Cancer Cell 18, 147–159
30. Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen,
A. G., and Lozano, G. (2001) Rescue of embryonic lethality in Mdm4-null
mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to
regulate p53. Nat. Genet. 29, 92–95
31. Itahana, K., Mao, H., Jin, A., Itahana, Y., Clegg, H. V., Lindström, M. S.,
Bhat, K. P., Godfrey, V. L., Evan, G. I., and Zhang, Y. (2007) Targeted
inactivation of Mdm2 RING finger E3 Ubiquitin ligase activity in the
FIGURE 7. MDM2 requires the AD and C-terminal residues to interact with
MDM2, whereas MDM2 requires the properly structured RING domain
and C-terminal residues to interact with MDMX. R, RING domain; C,
extreme C-terminal residues.
MDM2 Homo- and Heterodimers Require Distinct Domains
MAY 15, 2015 • VOLUME 290 • NUMBER 20 JOURNAL OF BIOLOGICAL CHEMISTRY 12949
mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12,
355–366
32. Montes de Oca Luna, R., Wagner, D. S., and Lozano, G. (1995) Rescue of
early embryonic lethality in mdm2-deficient mice by deletion of p53. Na-
ture 378, 203–206
33. Honda, R., and Yasuda, H. (2000) Activity of MDM2, a ubiquitin ligase,
toward or itself is dependent on the RING finger domain of the ligase.
Oncogene 19, 1473–1476
34. Kawai, H., Wiederschain, D., and Yuan, Z. M. (2003) Critical contribution
of the MDM2 acidic domain to p53 ubiquitination. Mol. Cell. Biol. 23,
4939 – 4947
35. Meulmeester, E., Frenk, R., Stad, R., de Graaf, P., Marine, J. C., Vousden,
K. H., and Jochemsen, A. G. (2003) Critical role for a central part of Mdm2
in the ubiquitylation of p53. Mol. Cell. Biol. 23, 4929 – 4938
36. Blattner, C., Hay, T., Meek, D. W., and Lane, D. P. (2002) Hypophos-
phorylation of Mdm2 augments p53 stability. Mol. Cell. Biol. 22,
6170 – 6182
37. Kulikov, R., Letienne, J., Kaur, M., Grossman, S. R., Arts, J., and Blattner, C.
(2010) Mdm2 facilitates the association of p53 with the proteasome. Proc.
Natl. Acad. Sci. U.S.A. 107, 10038 –10043
MDM2 Homo- and Heterodimers Require Distinct Domains
12950 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290 • NUMBER 20 • MAY 15, 2015
